Goldman Sachs

A Goldman Sachs analyst said that Myriad's third share repurchase program in less than 12 months "is reflective of slowing organic growth and increasing dependence on financial engineering to drive bottom-line growth."

In addition to initiating coverage of Cepheid, Gen-Probe, Myriad Genetics, and Qiagen, the investment bank also began coverage of Alere and Hologic.

Despite the drop in mass-spec sales, CEO Greg Lucier said "It was a very good quarter for our mass-spec business." Companywide revenues inched up 1 percent to $785M on a pro forma basis.

The change removes "drag from the revenue" but could also fuel speculation that Life Tech is considering divesting the unit. Officials reiterated the firm’s intent to "run the business for success."

News Scan

Premium

MDS, Cenix BioScience, Boehringer Ingelheim, Life Technologies, Molecular Devices

Pages

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.